HCPCS Level II code A9515 denotes choline C-11, a diagnostic radiopharmaceutical billed per study dose (up to 20 millicuries) used primarily in PET imaging. As an agent for molecular imaging, choline C-11 supports diagnostic evaluation of certain cancers and other metabolic processes; its use has implications for imaging workflows, supply chain for short‑half‑life radioisotopes, and payer coverage policies nationwide. Nationally, A9515 matters because it reflects reimbursement and utilization patterns for advanced PET diagnostics tied to specialized radiochemistry and time‑sensitive delivery.

Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The report outlines how these payers generally approach coverage for radiopharmaceuticals and imaging studies, while noting variations in prior authorization and site‑of‑service allowances.

Readers will find benchmarks on utilization and reimbursement frameworks, summaries of common billing and administrative considerations for A9515, and the clinical context for choline C-11 PET studies. The publication clarifies service settings, coding scope, and areas where policy updates or payer guidance commonly affect billing and access. Data not available in the input is noted where applicable.